From Novel Biotechnology Platform to Globally Competitive Cancer Company: Proacta Inc.
8,00 $ – 50,00 $
CASE STUDY. This decision-based case focuses on whether Proacta should raise more funds within New Zealand alone, syndicate a venture capital round with international investors, or seek a trade sale of the company.
